Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure

Current Heart Failure Reports

Volumn 14, Issue 4, 2017, Pages 338-349

  Dietl, Alexander ^a   Maack, Christoph ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Antioxidants; Calcium; CGP; Drug target; Empagliflozin; Energetic mismatch; Late sodium current; Mitochondria; MitoQ; NOX, statins; Oxidative stress; Ranolazine; Reactive oxygen species; Redox proteomics; ROS; Signalling; SS 31; Thiol switch

Indexed keywords

7 CHLORO 5 (2 CHLOROPHENYL) 1,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2(3H) ONE; ANTIOXIDANT; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; ELAMIPRETIDE; EMPAGLIFLOZIN; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; PEROXIREDOXIN; RANOLAZINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SODIUM GLUCOSE COTRANSPORTER 2; THIOL; THIOREDOXIN; BENZHYDRYL DERIVATIVE; CLONAZEPAM; GLUCOSIDE; THIAZEPINE DERIVATIVE;

ARRHYTHMOGENESIS; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CATALYST; DNA PROBE; ENERGY RESOURCE; GENE EXPRESSION; HEART FAILURE; HUMAN; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; REVIEW; SODIUM CURRENT; ANALOGS AND DERIVATIVES; HEART MITOCHONDRION; METABOLISM; RISK FACTOR;

ANTIOXIDANTS; BENZHYDRYL COMPOUNDS; CALCIUM; CLONAZEPAM; GLUCOSIDES; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; OXIDATION-REDUCTION; OXIDATIVE STRESS; RANOLAZINE; REACTIVE OXYGEN SPECIES; RISK FACTORS; THIAZEPINES;

EID: 85021257887     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-017-0347-7     Document Type: Review

References (172)

1. Münzel T, Camici G, Maack C, Bonetti N, Fuster V, Kovacic J. Impact of oxidative stress on the heart and vasculature. J. Am. Coll. Cardiol. 2017;in press.
2. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:154–60.
3. •• Nickel AG, von Hardenberg A, Hohl M, Löffler JR, Kohlhaas M, Becker J, et al. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab. 2015;22:472–84. In this paper, we discovered a novel mechanism how pathological cardiac workload increases oxidative stress in mitochondria, and that this oxidative stress played a causal role in the development of heart failure. It also suggests that targeting mitochondria with SS-31 to reduce oxidative stress rescued mortality in mice with heart failure.
4. Kohlhaas M, Nickel AG, Maack C. Mitochondrial energetics and calcium coupling in the heart. J Physiol. 2017;595:3753–3763.
5. 2).
6. • Swain L, Kesemeyer A, Meyer-Roxlau S, Vettel C, Zieseniss A, Güntsch A, et al. Redox imaging using cardiac myocyte-specific transgenic biosensor mice. Circ Res. 2016;119:1004–16. In this paper, transgenic mice were generated with cardiac myocyte-restricted expression of a redox-sensitive reporter coupled to glutaredoxin 1. Behaving like an endogenous protein, it quantifies glutathione redox potential with high temporal resolution and allows deeper insights into the balance between ROS production and elimination. As it is targeted to either mitochondrial matrix or cytoplasm, it remarkably increases spatial resolution.
7. Leichert LI, Dick TP. Incidence and physiological relevance of protein thiol switches. Biol Chem. 2015;396:389–99.
8. Dietl A, Stark K, Zimmermann ME, Meisinger C, Schunkert H, Birner C, et al. NT-proBNP Predicts Cardiovascular Death in the General Population Independent of Left Ventricular Mass and Function: Insights from a Large Population-Based Study with Long-Term Follow-Up. PLoS ONE 2016;11(10):e0164060. doi:10.1371/journal.pone.0164060.
9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;2016
10. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
11. Birner C, Ulucan C, Bratfisch M, Götz T, Dietl A, Schweda F, et al. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Naunyn Schmiedeberg's Arch Pharmacol. 2012;385:1117–25.
12. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res. 2012;111:1091–106.
13. Sag CM, Schnelle M, Zhang J, Murdoch CE, Kossmann S, Protti A, et al. Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell Nox2 on Blood Pressure. Circulation 2017;135: 2163–2177.
14. Brandes RP, Weissmann N, Schröder K. Redox-mediated signal transduction by cardiovascular NOX NADPH oxidases. J Mol Cell Cardiol. 2014;73:70–9.
15. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.
16. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120:713–35.
17. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase—mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008;275:3278–89.
18. Santin Y, Sicard P, Vigneron F, Guilbeau-Frugier C, Dutaur M, Lairez O, et al. Oxidative stress by monoamine oxidase-A impairs transcription factor EB activation and autophagosome clearance, leading to cardiomyocyte necrosis and heart failure. Antioxid Redox Signal. 2016;25:10–27.
19. Nickel A, Kohlhaas M, Maack C. Mitochondrial reactive oxygen species production and elimination. J Mol Cell Cardiol. 2014;73:26–33.
20. Aon MA, Cortassa S, O’Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta. 2010;1797:865–77.
21. Münzel T, Gori T, Keaney JF, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36:2555–64.
22. Santos CXC, Raza S, Shah AM. Redox signaling in the cardiomyocyte: from physiology to failure. Int J Biochem Cell Biol. 2016;74:145–51.
23. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res. 2001;88:529–35.
24. Zhang M, Prosser BL, Bamboye MA, Gondim ANS, Santos CX, Martin D, et al. Contractile function during angiotensin-II activation: increased Nox2 activity modulates cardiac calcium handling via phospholamban phosphorylation. J Am Coll Cardiol. 2015;66:261–72.
25. 2+-Dependent Arrhythmia in Hypertrophic Hearts by Regulating Mito-ROS-Dependent Oxidation and Activity of RyR. Cardiovasc. Res. 2017;113:343–353.
26. Wagner S, Dantz C, Flebbe H, Azizian A, Sag CM, Engels S, et al. NADPH oxidase 2 mediates angiotensin II-dependent cellular arrhythmias via PKA and CaMKII. J Mol Cell Cardiol. 2014;75:206–15.
27. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell. 2008;133:978–93.
28. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–62.
29. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652–8.
30. Maack C, Kartes T, Kilter H, Schäfers H-J, Nickenig G, Böhm M, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003;108:1567–74.
31. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245–8.
32. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28:506–14.
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–33.
34. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in pa- tients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
35. Cross AR, Segal AW. The NADPH oxidase of professional phagocytes—prototype of the NOX electron transport chain systems. Biochim Biophys Acta Bioenerg. 2004;1657:1–22.
36. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–9.
37. Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53:911–20.
38. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–43.
39. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.
40. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.
41. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–37.
42. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001;104:982–5.
43. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868–73.
44. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 2001;104:576–81.
45. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.
46. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2016;14:30–8.
47. Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58–65.
48. • Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488–96. This paper highlights the crosstalk of reactive oxygen species from NADPH oxidases and mitochondria in vascular cells. It shows that mitochondria amplify reactive oxygen species (ROS) formation from NADPH oxiase and vice versa, that NADPH oxidase-dependent ROS activate NADPH oxidase.
49. Dai D-F, Chen T, Szeto H, Nieves-Cintrón M, Kutyavin V, Santana LF, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011;58:73–82.
50. • Dai D-F, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintrón M, Chen T, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837–46. This paper shows that the NADPH oxidase-mitochondrial ROS crosstalk, as described by Doughan et al. (ref. 48) in vascular cells, also contributes to maladaptive cardiac remodeling and the development of diastolic heart failure in response to angiotensin II. It further shows that targeting mitochondrial ROS prevents this phenotype, while targeting cytosolic ROS in a rather non-specific way does not prevent angiotensin II-induced heart failure, giving a clue to why nonspecific antioxidants have been unsuccesful in patients at cardiovascular risk.
51. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol. 1997;29:207–16.
52. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation. 1997;96:2311–6.
53. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem. 1998;273:18092–8.
54. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci. 2009;106:8665–70.
55. Ristow M. Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits. Nat Med. 2014;20:709–11.
56. Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS, Dorn GW. Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res. 2014;115:348–53.
57. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.
58. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383:1933–43.
59. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;375:752–762.
60. Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356:1140–51.
61. Arcaro A, Pirozzi F, Angelini A, Chimenti C, Crotti L, Giordano C, et al. Novel perspectives in redox biology and pathophysiology of failing myocytes: modulation of the intramyocardial redox milieu for therapeutic interventions—a review article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. Oxid Med Cell Longev. 2016;2016:6353469.
62. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389:1253–67.
63. Birner C, Dietl A, Deutzmann R, Schröder J, Schmid P, Jungbauer C, et al. Proteomic profiling implies mitochondrial dysfunction in tachycardia-induced heart failure. J Card Fail. 2012;18:660–73.
64. Dietl A, Winkel I, Deutzmann R, Schröder J, Hupf J, Riegger G, et al. Interatrial differences of basal molecular set-up and changes in tachycardia-induced heart failure—a proteomic profiling study. Eur J Heart Fail. 2014;16:835–45.
65. Kuehne A, Emmert H, Soehle J, Winnefeld M, Fischer F, Wenck H, et al. Acute activation of oxidative pentose phosphate pathway as first-line response to oxidative stress in human skin cells. Mol Cell. 2015;59:359–71.
66. 2 sensitivity of GAPDH to facilitate metabolic adaptation. Nat Chem Biol. 2015;11:156–63.
67. Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res. 2017;113:411–21.
68. Bers DM. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda). 2006;21:380–7.
69. Kwong JQ, Lu X, Correll RN, Schwanekamp JA, Vagnozzi RJ, Sargent MA, et al. The mitochondrial calcium uniporter selectively matches metabolic output to acute contractile stress in the heart. Cell Rep. 2015;12:15–22.
70. Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014;505:335–43.
71. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.
72. 2 or oxidized glutathione, it reveales insights into the compartmentalized redox network and underscores the significance of mitochondrial metabolsim for cellular ROS handling.
73. Maack C, Böhm M. Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. J Am Coll Cardiol. 2011;58:83–6.
74. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001–14.
75. Letts JA, Fiedorczuk K, Sazanov LA. The architecture of respiratory supercomplexes. Nature. 2016;537:644–8.
76. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.
77. von Hardenberg A, Maack C. Mitochondrial Therapies in Heart Failure. Handb. Exp. Pharmacol. 2017;243:491–514.
78. Kohlhaas M, Maack C. Calcium release microdomains and mitochondria. Cardiovasc Res. 2013;98:259–68.
79. + increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation. 2010;121:1606–13.
80. Zhang H, Du Y, Zhang X, Lu J, Holmgren A. Glutaredoxin 2 reduces both thioredoxin 2 and thioredoxin 1 and protects cells from apoptosis induced by auranofin and 4-hydroxynonenal. Antioxid Redox Signal. 2014;21:669–81.
81. 2+ exchange prevents sudden death in a guinea pig model of heart failure. Circ Res. 2014;115:44–54.
82. 2+ channels. Circulation. 2009;119:2435–43.
83. Weber CR, Piacentino V, Houser SR, Bers DM. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation. 2003;108:2224–9.
84. 2+ exchanger. Cell Calcium. 2012;52:9–15.
85. 2+-induced NAD(P)H production and modulating matrix redox state. J Biol Chem. 2014;289:20377–85.
86. Armoundas AA, Hobai IA, Tomaselli GF, Winslow RL, O’Rourke B. Role of sodium-calcium exchanger in modulating the action potential of ventricular myocytes from normal and failing hearts. Circ Res. 2003;93:46–53.
87. 2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res. 2006;99:172–82.
88. Rydström J. Mitochondrial NADPH, transhydrogenase and disease. Biochim Biophys Acta Bioenerg. 2006;1757:721–6.
89. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276:4588–96.
90. Ross MF, Kelso GF, Blaikie FH, James AM, Cochemé HM, Filipovska A, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 2005;70:222–30.
91. Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–56.
92. James AM, Cochemé HM, Smith RAJ, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280:21295–312.
93. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RAJ, Murphy MP, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005;19:1088–95.
94. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RAJ, Cochemé HM, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322–8.
95. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J. 2009;96:1388–98.
96. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1095–102.
97. Vergeade A, Mulder P, Vendeville-Dehaudt C, Estour F, Fortin D, Ventura-Clapier R, et al. Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ. Free Radic Biol Med. 2010;49:748–56.
98. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25:1670–4.
99. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019–26.
100. James AM, Sharpley MS, Manas A-RB, Frerman FE, Hirst J, Smith RAJ, et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem. 2007;282:14708–18.
101. Doughan AK, Dikalov SI. Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal. 2007;9:1825–36.
102. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029–50.
103. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250–61.
104. Dai D-F, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ Heart Fail. 2013;6:1067–76.
105. Gibson CM, Giugliano RP, Kloner RA, Bode C, Tendera M, Jánosi A, et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37:1296–303.
106. Silva FSG, Simoes RF, Couto R, Oliveira PJ. Targeting mitochondria in cardiovascular diseases. Curr Pharm Des. 2016;22:5698–717.
107. Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J. 2015;29:4766–71.
108. Mailloux RJ. Application of mitochondria-targeted pharmaceuticals for the treatment of heart disease. Curr Pharm Des. 2016;22:4763–79.
109. Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J Cardiol. 2014;6:1091–9.
110. Fetisova EK, Chernyak BV, Korshunova GA, Muntyan MS, Skulachev VP. Mitochondria-targeted antioxidants as a prospective therapeutic strategy for multiple sclerosis. Curr Med Chem. 2017;24:1–1.
111. Reddy AP, Reddy PH. Mitochondria-targeted molecules as potential drugs to treat patients with Alzheimer’s disease. Prog Mol Biol Transl Sci. 2017;146:173–201.
112. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta. 2016;1863:1066–1077.
113. Yang Y, Karakhanova S, Hartwig W, D’Haese JG, Philippov PP, Werner J, et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol. 2016;231:2570–81.
114. 2+ exchanger. Biochem Pharmacol. 1988;37:4399–403.
115. 2+ exchange of heart mitochondria by benzothiazepine CGP-37157. J Cardiovasc Pharmacol. 1993;21:595–9.
116. 2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res. 2008;103:279–88.
117. Liu T, Brown DA, O’Rourke B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. J Mol Cell Cardiol. 2010;49:728–36.
118. 2+ exchange prevents sudden death in a guinea pig model of heart failure. Circ Res. 2014;115:44–54. This paper shows that targeting mitochondrial ion transporters to re-calibrate the energy supply and demand mismatch can prevent maladaptive cardiac remodeling, left ventricular dysfunction and lethal arrhythmias in a guinea pig model of heart failure. It adds further evidence on an in vivo basis to the concept that the elevation of cytosolic sodium concentrations in failing cardiac myocytes contributes to maladaptive remodeling and heart failure development by decreasing mitochondrial calcium uptake.
119. Choudhary V, Kaddour-Djebbar I, Alaisami R, Kumar M, Bollag W. Mitofusin 1 degradation is induced by a disruptor of mitochondrial calcium homeostasis, CGP37157: a role in apoptosis in prostate cancer cells. Int J Oncol. 2014;44:1767–73.
120. 2+ channels. Cell Death Dis. 2014;5:e1156.
121. i handling in the failing human heart. Cardiovasc Res. 2003;57:874–86.
122. + channels. J Clin Invest. 2006;116:3127–38.
123. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail. 2007;9:219–27.
124. + current. Basic Res Cardiol. 2011;106:263–72.
125. 2+ mishandling in isolated ventricular myocytes. J Mol Cell Cardiol. 2014;76:247–56.
126. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, et al. Reactive oxygen species-activated Ca/calmodulin kinase II is required for late INa augmentation leading to cellular Na and Ca overload. Circ Res. 2011;108:555–65.
127. Yang Z, Kirton HM, Al-Owais M, Thireau J, Richard S, Peers C, et al. Epac2-Rap1 Signaling Regulates Reactive Oxygen Species Production and Susceptibility to Cardiac Arrhythmias. Antioxid. Redox Signal. 2016; ahead of print. doi:10.1089/ars.2015.6485.
128. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2007;116
129. Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A. Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol. 2017;227:556–64.
130. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S169–77.
131. Cappetta D, Esposito G, Coppini R, Piegari E, Russo R, Ciuffreda LP, et al. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. Br. J. Pharmacol. 2017; ahead of print doi:10.1111/bph.13791.
132. Sossalla S, Wagner S, Rasenack ECL, Ruff H, Weber SL, Schöndube FA, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts—role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45:32–43.
133. Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino T, et al. Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy clinical perspective. Circ Hear Fail. 2017;10:e003565.
134. Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S, et al. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovasc Res. 2016;109:90–102.
135. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127:575–84.
136. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary-thrombolysis in myocardial infarction 36) trial. J Am Coll Cardiol. 2010;55:1189–96.
137. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1:115–22.
138. Rayner-Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc. 2016;5
139. Maier LS, Sossalla S. The late Na current as a therapeutic target: where are we? J Mol Cell Cardiol. 2013;61:44–50.
140. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311–23.
141. + current. J Physiol. 2015;593:1429–42.
142. Yang P-C, El-Bizri N, Romero L, Giles WR, Rajamani S, Belardinelli L, et al. A computational model predicts adjunctive pharmacotherapy for cardiac safety via selective inhibition of the late cardiac Na current. J Mol Cell Cardiol. 2016;99:151–61.
143. Baczko I, Liknes D, Yang W, Hamming KC, Searle G, Jaeger K, et al. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. Br J Pharmacol. 2014;171:92–106.
144. •• Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568–73. This paper makes the interesting observation that empagliflozin may have off-target effects on cardiac myocytes, reducing cytosolic sodium and increasing mitochondrial calcium. Whether this effect contributes to the beneficial effects of empagliflozin on the development of heart failure in patients with diabetes is currently still unresolved.
145. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90.
146. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89.
147. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84.
148. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
149. Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni A Pietro, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int. J. Cardiol. 2017;241:450–456.
150. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134:752–72.
151. Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive MedicationNovelty and significance. Hypertension. 2016;68:1355–64.
152. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–8.
153. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–14.
154. i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003;57:1015–24.
155. Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017;16:48.
156. 2 signaling. Nat Chem Biol. 2015;11:64–70.
157. Wadley AJ, Aldred S, Coles SJ. An unexplored role for peroxiredoxin in exercise-induced redox signalling? Redox Biol. 2016;8:51–8.
158. Jarvis RM, Hughes SM, Ledgerwood EC. Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells. Free Radic Biol Med. 2012;53:1522–30.
159. Wood ZA, Schröder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.
160. Meng G, Zhao S, Xie L, Han Y, Ji Y. Protein S-sulfhydration by hydrogen sulfide in cardiovascular system. Br. J. Pharmacol. 2017; ahead of print doi:10.1111/bph.13825.
161. Nietzel T, Mostertz J, Hochgräfe F, Schwarzländer M. Redox regulation of mitochondrial proteins and proteomes by cysteine thiol switches. Mitochondrion. 2017;33:72–83.
162. Boronat S, Domènech A, Hidalgo E. Proteomic characterization of reversible thiol oxidations in proteomes and proteins. Antioxid Redox Signal. 2017;26:329–44.
163. Duan J, Gaffrey MJ, Qian W-J. Quantitative proteomic characterization of redox-dependent post-translational modifications on protein cysteines. Mol. BioSyst. 2017;13:816–829.
164. Anderson ME. Oxidant stress promotes disease by activating CaMKII. J Mol Cell Cardiol. 2015;89:160–7.
165. Qin L, Reger AS, Guo E, Yang MP, Zwart P, Casteel DE, et al. Structures of cGMP-dependent protein kinase (PKG) Iα leucine zippers reveal an Interchain disulfide bond important for dimer stability. Biochemistry. 2015;54:4419–22.
166. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schröder E, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317:1393–7.
167. Nakamura T, Ranek MJ, Lee DI, Shalkey Hahn V, Kim C, Eaton P, et al. Prevention of PKG1α oxidation augments cardioprotection in the stressed heart. J Clin Invest. 2015;125:2468–72.
168. Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schröder E, Wait R, et al. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. J Biol Chem. 2006;281:21827–36.
169. Burgoyne JR, Rudyk O, Cho H, Prysyazhna O, Hathaway N, Weeks A, et al. Deficient angiogenesis in redox-dead Cys17Ser PKARIα knock-in mice. Nat Commun. 2015;6:7920.
170. Limbu S, Hoang-Trong TM, Prosser BL, Lederer WJ, Jafri MS. Modeling local X-ROS and calcium signaling in the heart. Biophys J. 2015;109:2037–50.
171. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie L-H, et al. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res. 2013;112:651–63.
172. Matsushima S, Kuroda J, Ago T, Zhai P, Ikeda Y, Oka S, et al. Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-1α and upregulation of peroxisome proliferator-activated receptor-α. Circ Res. 2013;112:1135–49.